Rockwell Medical, Inc. to Report Second Quarter 2021 Financial and Operating Results on August 16, 2021

Rhea-AI Summary

Rockwell Medical (Nasdaq: RMTI) announced a conference call on August 16, 2021, at 4:30 p.m. ET to discuss its financial results for Q2 2021 and operational updates. Investors can join the call by dialing (877) 377-7548 locally or (760) 666-3756 internationally, referencing conference ID 1254179. A live webcast will also be available on the company's investor website with an archived version accessible for 30 days. Rockwell Medical is focused on transforming iron deficiency treatment with its proprietary Ferric Pyrophosphate Citrate technology.

WIXOM, Mich., July 29, 2021 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (Nasdaq: RMTI), a biopharmaceutical company dedicated to transforming the treatment of iron deficiency and anemia management and improving outcomes for patients around the world, today announced that it will host a conference call on Monday, August 16, 2021, at 4:30 p.m. ET to discuss its financial results for the three months ended June 30, 2021, and recent operational highlights.

To access the conference call, please dial (877) 377-7548 (local) or (760) 666-3756 (international) at least 10 minutes prior to the start time and refer to conference ID 1254179. A live webcast of the call will be available under "Events & Presentations" in the Investor section of the Company's website, https://ir.rockwellmed.com/. An archived webcast will be available on the Company's website approximately two hours after the event and will be available for 30 days.

To submit questions in advance, please email your questions to invest@rockwellmed.com.

About Rockwell Medical

Rockwell Medical is a commercial-stage biopharmaceutical company developing and commercializing its next-generation parenteral iron technology platform, Ferric Pyrophosphate Citrate (FPC), which has the potential to lead transformative treatments for iron deficiency in multiple disease states, reduce healthcare costs and improve patients’ lives. The Company has two FDA-approved therapies indicated for patients undergoing hemodialysis, which are the first two products developed from the FPC platform. The Company is developing FPC for the treatment of iron deficiency in patients outside of dialysis, who are receiving intravenous medications in the home infusion setting, a large and rapidly growing segment of healthcare, and where these patients suffer from chronic diseases associated with high incidence of iron deficiency and anemia. In addition, Rockwell Medical is one of two major suppliers of life-saving hemodialysis concentrate products to kidney dialysis clinics in the United States. For more information, visit www.RockwellMed.com.

CONTACTS

Investors:
Argot Partners
212.600.1902
Rockwell@argotpartners.com

Media:
David Rosen
Argot Partners
212.600.1902
david.rosen@argotpartners.com

FAQ

When is the Rockwell Medical conference call for financial results?

The Rockwell Medical conference call is scheduled for August 16, 2021, at 4:30 p.m. ET.

What is the conference ID for the Rockwell Medical call?

The conference ID for the Rockwell Medical call is 1254179.

How can I access the Rockwell Medical conference call?

You can access the Rockwell Medical conference call by dialing (877) 377-7548 locally or (760) 666-3756 internationally.

What will Rockwell Medical discuss in the upcoming conference call?

Rockwell Medical will discuss its financial results for the three months ended June 30, 2021, and recent operational highlights.

Where can I find the archived webcast of the Rockwell Medical call?

The archived webcast of the Rockwell Medical call will be available on the company's investor website approximately two hours after the event and for 30 days.

What is the focus of Rockwell Medical's biopharmaceutical developments?

Rockwell Medical focuses on transforming iron deficiency and anemia management with its Ferric Pyrophosphate Citrate technology.